Showing 4191-4200 of 5623 results for "".
- Orasis Pharmaceuticals Concludes Phase 3 Clinical Trials for Presbyopia Candidatehttps://modernod.com/news/orasis-pharmaceuticals-concludes-phase-3-clinical-trials-for-presbyopia-candidate/2480699/Orasis Pharmaceuticals announced the completion of its NEAR-1 and NEAR-2 phase 3 clinical studies. “Orasis is committed to reshaping vision possibilities by developing a presbyopia eye drop with the patient in mind,” said Elad Kedar, Chief Executive Officer of Orasis. &ldquo
- RG6501 (OpRegen) Full Phase 1/2a Results to Be Presented at ARVO Annual Meetinghttps://modernod.com/news/rg6501-opregen-full-phase-12a-results-to-be-presented-at-arvo-annual-meeting/2480697/Lineage Cell Therapeutics announced that full results from a phase 1/2a clinical study of RG6501 (OpRegen), a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD), will be presented at the 2022 Associ
- Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink Therapyhttps://modernod.com/news/glaukos-announces-commencement-of-phase-2-corneal-health-clinical-program-for-third-generation-ilink-therapy/2480696/Glaukos announced that it has commenced a phase 2 clinical program for its third-generation iLink therapy designed to treat keratoconus. Glaukos’ iLink pharmaceutical platform consists of novel single-use drug formulations that are bio-activa
- SECO International and National Academy of Opticianry Expand Partnership to Bring Optician-Focused Education to SECO 2023https://modernod.com/news/seco-international-and-national-academy-of-opticianry-expand-partnership-to-bring-optician-focused-education-to-seco-2023/2480695/SECO International announced that it has expanded a partnership with the National Academy of Opticianry (NAO) to bring a dedicated educational track for opticians to SECO 2023. The NAO, founded in 1963, represents opticians worldwide and is dedicated solely to education and training of all o
- UArizona Engineer Leads $1M Project to Fight Vision Losshttps://modernod.com/news/uarizona-engineer-leads-1m-project-to-fight-vision-loss/2480692/Eye infections are common in rural farming communities. A scratch on the cornea caused during agricultural work can get infected and turn into a scar, then an ulcer. These corneal ulcers cause blindness and visual impairment in 4.3 million people worldwide every year, according to data published
- NovaSight Announces Successful Results of Pivotal Amblyopia Treatment Trialhttps://modernod.com/news/novasight-announces-successful-results-of-pivotal-amblyopia-treatment-trial/2480689/NovaSight announced positive pivotal data from its multicenter, randomized, controlled trial of CureSight, an eye-tracking based, digital treatment device for amblyopia (lazy eye). The study, which randomized 103 participants aged 4 to 9, compared the improvement in visual outcomes achieved
- Théa Completes its Acquisition of Akorn’s Branded Ophthalmic Productshttps://modernod.com/news/thea-completes-its-acquisition-of-akorns-branded-ophthalmic-products/2480688/Théa Pharma announced the completion of its previously announced acquisition of seven branded ophthalmic products from Akorn. The transaction expands Théa’s eye care portfolio in the United States. Financial terms of the deal were not disclosed. &
- DORC Launches Eva Nexushttps://modernod.com/news/dorc-launches-eva-nexus/2480687/DORC International announced the launch of Eva Nexus, a device designed to improve efficiency and control in retina, cataract and combined surgery. Eva Nexus introduces multiple innovations in surgical performance and efficiency, including SmartIOP that combines with the existing E
- Proof of COVID-19 Vaccination and Face Coverings Will Not Be Required to Attend Vision Expo East, March 31-April 3, 2022https://modernod.com/news/proof-of-covid-19-vaccination-and-face-coverings-will-not-be-required-to-attend-vision-expo-east-march-31-april-3-2022/2480686/The Vision Council and RX, co-organizers of Vision Expo, share that, in accordance with New York State and New York City guidelines and the updated requirements of the Javits Center, proof of COVID-19 vaccination and face coverings will not be required to attend Vision Expo East, tak
- Oculis Announces Licensing Agreement for Neuroprotective Drug Candidate for Glaucoma from Accure Therapeuticshttps://modernod.com/news/oculis-announces-licensing-agreement-for-neuroprotective-drug-candidate-for-glaucoma-from-accure-therapeutics/2480683/Oculis and Accure Therapeutics announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01, a potentially disease-modifying therapy to protect and prevent damage to the optic nerve and retina. Under the terms of the agreement, Accure